- Tauqeer Karim
- Vice President, Drug and Device Safety Officer
- Fresenius Medical Care
Dr. Karim is an accomplished nephrologist with a special interest in safety surveillance. He has vast clinical experience in managing patients with kidney disease, including those on dialysis and in preparation for kidney transplants. Dr. Karim trained at Tufts University School of Medicine, Division of Nephrology and at the Sackler Graduate School of Biomedical Science, Boston, MA for a post-doctoral fellowship training focused in epidemiology and clinical care outcomes, this also included course on National Health Policy at the Heller School, Brandeis University, Waltham, MA affiliated with Schneider Institute of Health. His MS dissertation was “Meta-analysis of the risk of kidney failure following recombinant erythropoietin therapy with severely decreased kidney function”. During his post-doctoral fellowship training at Tufts, he served as a Clinical Research Fellow at the New England Medical Center as an Evidence Based Medicine Team which published the first KDOQI (Kidney Disease Outcomes and Quality Initiatives) clinical practice guidelines on staging, stratifying and classification of chronic kidney disease (CKD) in 2000 under the auspices of the National Kidney Foundation. Dr. Karim subsequently was a Research Fellow at CBER ; Division of Biostatistics and Epidemiology, FDA as an Oakridge Fellow sponsored through Oakridge Associated Universities. While at the FDA he was a medical reviewer for post marketing surveillance of therapeutic biological products for signal detection using the DA’s AERS database and represented the Agency in the 2003 Arthritis Advisory National Committee Meeting on safety and efficacy of anti -TNF alpha therapy on rheumatoid arthritis and Crohn’s disease. Subsequently, he held Safety Physician positions in leading pharmaceutical companies such as Allergan, Schering- Plough, Novartis, Merck and Vertex Pharmaceutical. Since 2015 he has served as the Vice President, Drug & Device Safety Officer and leads the Pharmacovigilance Department at Fresenius Medical Care – North America based in Waltham. Fresenius is a leading provider of dialysis globally for patients with end stage acute and chronic kidney disease.